Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

150.94 +2.32 (+1.56%)
Streaming Delayed Price Updated: 3:25 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
News headline image
The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash... 
Via Finterra
Topics Initial Public Offering Intellectual Property World Trade
News headline image
Retirees: Collect a High Dividend While Diversifying Your Portfolio With This ETF ↗
The Vanguard International High Dividend Yield ETF holds more than 1,500 stocks and yields 3.3%. 
Via The Motley Fool
Topics ETFs Retirement
News headline image
3 ETFs Built for the Volatile Market We're Seeing in March 2026 ↗
These ETFs can handle volatile markets. 
Via The Motley Fool
Topics ETFs Economy Stocks
Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income ↗
Via Chartmill
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals ↗
Via Chartmill
News headline image
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug ↗
Novartis to acquire SNV4818 for $3 billion, targeting PIK3CA-mutated breast cancer with a potentially safer, precision-based approach. 
Via Benzinga
News headline image
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients ↗
FDA approves Novartis' Cosentyx for moderate to severe hidradenitis suppurativa in patients aged 12 and older, expanding treatment options. 
Via Benzinga
News headline image
VYMI: This International ETF Could Help You Earn Higher Dividends ↗
If you want international stock exposure with a chance for higher dividend yields, this Vanguard ETF could be a good buy. 
Via The Motley Fool
Topics ETFs
News headline image
3 ETFs to Avoid as Oil Shock Hits Markets ↗
Via MarketBeat
Topics ETFs
News headline image
Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy
Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER... 
Via MarketMinute
News headline image
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering... 
Via Finterra
Topics Economy Intellectual Property Lawsuit
News headline image
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now ↗
One is speculative, the other is a reliable blue chip company. 
Via The Motley Fool
Topics Intellectual Property
News headline image
As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗
Via MarketBeat
Topics ETFs
News headline image
Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement ↗
Novartis reached a confidential settlement with Henrietta Lacks' family, resolving a second lawsuit over the nonconsensual use of HeLa cells. 
Via Benzinga
Topics Lawsuit
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗
Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026. 
Via The Motley Fool
Topics Stocks
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total... 
Via MarketMinute
Topics Intellectual Property
News headline image
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio? ↗
It has the qualities of a buy-and-forget stock. 
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
Arvinas (ARVN) Q4 2025 Earnings Call Transcript ↗
Arvinas (ARVN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short ↗
Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy. 
Via The Motley Fool
Topics Stocks
News headline image
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades ↗
Novartis has a solid portfolio of drugs and a pipeline that should keep the business humming. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer
NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both... 
Via MarketMinute
News headline image
A Look Into Novartis Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Promethos Capital Liquidates $4 Million Sprouts Farmers Market Position: Should Investors Sell, Too? ↗
Sprouts Farmers Market runs a national grocery chain focused on fresh, natural, and organic foods for health-conscious shoppers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗
Goldman Sachs expects European and emerging-market equities to beat the U.S. stock market over the next decade. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise ↗
Novartis shared final Phase 3 results showing Vanrafia may slow kidney function decline in adults with IgA nephropathy. 
Via Benzinga
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,... 
Via MarketMinute
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.